Brokerages Set GH Research PLC (NASDAQ:GHRS) PT at $30.86

Shares of GH Research PLC (NASDAQ:GHRS) have been assigned a consensus rating of “Buy” from the seven brokerages that are presently covering the stock, Marketbeat reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 1-year price target among brokerages that have covered the stock in the last year is $30.86.

A number of analysts have recently issued reports on GHRS shares. Guggenheim began coverage on GH Research in a research report on Thursday, March 13th. They issued a “buy” rating and a $32.00 price objective for the company. HC Wainwright reissued a “buy” rating and issued a $40.00 target price on shares of GH Research in a research report on Monday, January 27th. Stifel Nicolaus upped their price target on shares of GH Research from $18.00 to $32.00 and gave the company a “buy” rating in a research note on Thursday, February 27th. Royal Bank of Canada initiated coverage on shares of GH Research in a research note on Friday, March 7th. They issued an “outperform” rating and a $31.00 price objective for the company. Finally, Cantor Fitzgerald started coverage on shares of GH Research in a research report on Thursday, February 13th. They set an “overweight” rating and a $14.00 target price on the stock.

Institutional Investors Weigh In On GH Research

A number of large investors have recently bought and sold shares of the company. BNP Paribas Financial Markets bought a new stake in shares of GH Research during the 4th quarter worth approximately $44,000. Two Sigma Investments LP acquired a new position in GH Research during the fourth quarter valued at approximately $117,000. Millennium Management LLC bought a new stake in GH Research during the fourth quarter worth $145,000. AdvisorShares Investments LLC boosted its holdings in shares of GH Research by 15.4% in the 4th quarter. AdvisorShares Investments LLC now owns 36,011 shares of the company’s stock valued at $252,000 after purchasing an additional 4,806 shares in the last quarter. Finally, Northern Trust Corp increased its stake in shares of GH Research by 26.8% in the 4th quarter. Northern Trust Corp now owns 40,834 shares of the company’s stock valued at $286,000 after purchasing an additional 8,641 shares during the last quarter. 56.90% of the stock is currently owned by institutional investors and hedge funds.

GH Research Trading Up 2.3 %

NASDAQ GHRS opened at $10.09 on Tuesday. The company has a market cap of $524.96 million, a PE ratio of -12.77 and a beta of 0.84. GH Research has a 12 month low of $6.00 and a 12 month high of $20.50. The stock has a 50 day moving average of $11.92 and a 200-day moving average of $9.42.

GH Research (NASDAQ:GHRS) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.17) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.06. As a group, sell-side analysts predict that GH Research will post -0.8 EPS for the current fiscal year.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).